SRRK — Scholar Rock Holding Share News
0.000.00%
Last trade - 00:00Brief: FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
Brief: Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Analog Devices, Autodesk, Salesforce
Regeneron rises after FDA's extended decision date for eye drug comes ahead of expectations
Brief: Scholar Rock Reports New Employee Inducement Grants
Scholar Rock Holding Corp reports results for the quarter ended June 30 - Earnings Summary
Biopharma Scholar Rock Q2 net loss widens, no revenue
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
US STOCKS-S&P 500 ends nearly flat, gives back gains; Fed's Powell says inflation to rise
US STOCKS-S&P 500 ends near flat, gives back gains after Fed's Powell speaks
US STOCKS-Indexes briefly add to gains after Fed statement, trade volatile
U.S. STOCKS ON THE MOVE-SanDisk, MakeMyTrip, Coinbase
US STOCKS-Wall St indexes rise ahead of Fed's interest rate verdict
U.S. STOCKS ON THE MOVE-Affirm, Guild Holdings, Circle Internet
Factbox: Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
Scholar Rock hits 3-month high as its drug helped preserve muscle in overweight patients
US STOCKS-Wall Street edged higher ahead of Fed's interest rate verdict
US STOCKS-Wall Street indexes set for subdued open ahead of Fed's interest rate verdict
U.S. STOCKS ON THE MOVE-Circle, Guild Holdings, Steel Dynamics